Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem cell-based therapy to treat severe aplastic ...

About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...

While the China-targeting Biosecure Act failed to pass muster in a key defense spending bill last year, a retooled version of ...